NovoCure Overview
NovoCure (NVCR) has a ROE of -43.94%, below the Healthcare sector average of 21.28%.
Get informed when a big investor buys or sells
+ Follow-43.94%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
NovoCure (NVCR) currently reports a ROE of -43.94%. That is below the Healthcare sector average of 21.28%. Use the charts on this page to explore NovoCure's ROE history and peer comparisons.
NovoCure's ROE of -43.94% is lower than the Healthcare sector average of 21.28%. That is roughly 306.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but NovoCure's current -43.94% should be judged against Healthcare norms (sector average: 21.28%) and against NVCR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -43.94%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for NovoCure, and consider following NVCR for alerts when major investors trade the stock.
NovoCure is classified in the Healthcare sector. On ROE, it currently shows -43.94% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NVCR with unrelated industries.
